249 related articles for article (PubMed ID: 18506108)
1. Association between erythropoietin requirements and antihypertensive agents.
Yano S; Suzuki K; Iwamoto M; Urushidani Y; Yokogi H; Kusakari M; Aoki A; Sumi M; Kitamura K; Sanematsu H; Gohbara M; Imamura S; Sugimoto T
Nephron Clin Pract; 2008; 109(1):c33-9. PubMed ID: 18506108
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.
Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY;
J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
4. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis.
Nakamoto H; Kanno Y; Okada H; Suzuki H
Adv Perit Dial; 2004; 20():111-6. PubMed ID: 15384808
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
8. Biocompatibility and permeability of dialyzer membranes do not affect anemia, erythropoietin dosage or mortality in japanese patients on chronic non-reuse hemodialysis: a prospective cohort study from the J-DOPPS II study.
Yokoyama H; Kawaguchi T; Wada T; Takahashi Y; Higashi T; Yamazaki S; Fukuhara S; Akiba T; Akizawa T; Asano Y; Kurokawa K; Saito A;
Nephron Clin Pract; 2008; 109(2):c100-8. PubMed ID: 18596379
[TBL] [Abstract][Full Text] [Related]
9. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Odabas AR; Cetinkaya R; Selcuk Y; Keles S; Bilen H
Panminerva Med; 2003 Mar; 45(1):59-62. PubMed ID: 12682621
[TBL] [Abstract][Full Text] [Related]
10. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
[TBL] [Abstract][Full Text] [Related]
11. [Study of immutable variables determining rHuEPO dose requirements on hemodialysis patients].
Gascón A; Virto R; Lou LM; Pernaute R; Moreno R; Pérez J; Aladrén MJ; Moragrega B; Castillón E; Gómez R; Vives PJ; Alvarez R; García FJ; Castilla J; Gutiérrez Colón JA
Nefrologia; 2005; 25(5):535-42. PubMed ID: 16392304
[TBL] [Abstract][Full Text] [Related]
12. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
13. rHuEPO dose inversely correlated with the number of circulating CD34+ cells in maintenance hemodialysis patients.
Kohagura K; Ohya Y; Miyagi S; Ishida A; Yakabi S; Iseki K; Yamane N; Takishita S
Nephron Clin Pract; 2008; 108(1):c41-6. PubMed ID: 18087171
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and severity of anemia in pediatric hemodialysis patients.
Azhir A; Nasiri J; Gheisari A
Saudi Med J; 2007 Feb; 28(2):249-53. PubMed ID: 17268705
[TBL] [Abstract][Full Text] [Related]
15. [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients].
Hatano M; Yoshida T; Mimuro T; Kimata N; Tsuchiya K; Sanaka T; Nihei H
Nihon Jinzo Gakkai Shi; 2000 Oct; 42(8):632-9. PubMed ID: 11195399
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of treating anemia in patients undergoing chronic dialysis with small doses of human recombinant erythropoietin].
Marusza W; Matuszkiewicz-Rowińska J; Tomik Z; Andrzejewski A; Rokicka M; Paszkowska M; Drygieniec D; Bobilewicz D; Zawadzka M; Abbas-Fatah A
Pol Tyg Lek; 1995 Oct; 50(40-44):15-8, 31. PubMed ID: 8650050
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model.
Saito I; Kobayashi M; Matsushita Y; Mori A; Kawasugi K; Saruta T
Hypertens Res; 2008 Jul; 31(7):1373-83. PubMed ID: 18957808
[TBL] [Abstract][Full Text] [Related]
19. Factors contributing to higher hematocrit levels in hemodialysis patients not receiving recombinant human erythropoietin.
Takeda A; Toda T; Shinohara S; Mogi Y; Matsui N
Am J Kidney Dis; 2002 Jul; 40(1):104-9. PubMed ID: 12087567
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
